Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038150 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| SCHEMBL27018154 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| SCHEMBL13789337 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| SCHEMBL9391670 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| SCHEMBL3626700 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| SCHEMBL12238110 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| SCHEMBL15140 | 1.00 | HSD17B10 (0.52) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| Hydrochloric Acid SCHEMBL2150998 | 0.98 | ALDH1A1 (0.50) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| Hydrochloric Acid SCHEMBL2192702 | 0.98 | ALDH1A1 (0.50) | HSD17B10ALDH1A1TSHRPAOXKMT2A | |
| Hydrochloric Acid SCHEMBL1128116 | 0.98 | ALDH1A1 (0.50) | HSD17B10ALDH1A1TSHRPAOXKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-9550704-B2 | Method for synthesizing radiopharmaceuticals using a cartridge | FUTURECHEM CO., LTD. (KR) | 2017-01-24 | — | — | US | disclosed |
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | FUTURECHEM CO., LTD. (KR) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | ADCYAP1R1, PAICS, SSTR5 | HSD17B10 3482/4885ALDH1A1 2900/4885TSHR 71/4885 |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | KLK3, FOLH1, TMEM14C | HSD17B10 1624/4885ALDH1A1 2048/4885TSHR 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.